featured
Clinical Utility of Cardiovascular Risk Scores for the Identification of People With Type 2 Diabetes More Likely to Benefit From Either GLP-1RA or SGLT2i Therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Diabetes Care
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Clinical Utility of Cardiovascular Risk Scores for Identification of People With Type 2 Diabetes More Likely to Benefit From Either GLP-1 Receptor Agonist or SGLT2 Inhibitor Therapy
Diabetes Care 2022 Aug 01;45(8)1900-1906, JW Sacre, DJ Magliano, JE ShawFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.